NEW YORK, NY – Trifecta Med Spa, Trifecta Health, and Edward Fruitman, M.D. (collectively, “Trifecta”) have issued a formal correction and clarification regarding recent statements circulating online. The announcement aims to dispel any misconceptions about the organization’s relationship with pharmaceutical giant Eli Lilly and its direct-to-consumer platform, LillyDirect®.
According to the statement, Trifecta does not have any contractual relationship, partnership, agreement, affiliation, or cooperation arrangement of any kind with Eli Lilly, LillyDirect®, or any Eli Lilly subsidiary. Conversely, Eli Lilly and LillyDirect® have not entered into any contractual relationship or partnership with Trifecta. This clarification is significant given the growing interest in weight-loss medications such as Zepbound®, an Eli Lilly product, and the potential for confusion among patients seeking treatment.
Trifecta explicitly stated that it does not endorse, promote, or show preference for any Eli Lilly products, including Zepbound®, in the course of its medical or weight-loss services. This commitment to neutrality is intended to reassure patients that their treatment plans are based solely on medical evidence and individual needs, not commercial agreements.
The organization further emphasized its dedication to collaborating with any licensed pharmacy or pharmacy service provider that can offer the best quality of care, value, and pricing for its patients. Trifecta has not entered — nor does it plan to enter — into any exclusive pharmacy arrangement, product preference policy, or partnership with Eli Lilly or LillyDirect®. This approach underscores the importance of maintaining independence from manufacturer influence in healthcare decisions.
Trifecta Health and Trifecta Med Spa remain committed to providing evidence-based, patient-centered weight-loss and wellness services, free of any manufacturer or pharmacy influence. For more information about their weight management program, visit https://trifectamedspanyc.com/weight-management-program.
This clarification is particularly important in the current healthcare landscape, where direct-to-consumer pharmaceutical platforms and manufacturer partnerships are becoming more common. Patients seeking weight-loss treatments may encounter conflicting information about which providers have ties to specific drug manufacturers. By explicitly denying any relationship with Eli Lilly or LillyDirect®, Trifecta aims to build trust and transparency with its patients.
The implications of this announcement extend beyond Trifecta’s practice. It highlights the broader issue of how healthcare providers’ relationships with pharmaceutical companies can affect patient care. As the demand for weight-loss medications continues to rise, patients are increasingly advised to seek providers who prioritize clinical judgment over commercial interests. Trifecta’s statement serves as a model for transparency in this evolving field.
